Adma Biologics Inc. (NASDAQ:ADMA) has been given a consensus broker rating score of 2.33 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. Adma Biologics’ rating score has declined by 133% from three months ago as a result of various analysts’ ratings changes.
Analysts have set a 1 year consensus target price of $13.25 for the company and are anticipating that the company will post ($0.40) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Adma Biologics an industry rank of 108 out of 265 based on the ratings given to its competitors.
A number of analysts have recently issued reports on ADMA shares. Maxim Group downgraded shares of Adma Biologics from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Raymond James Financial Inc. cut shares of Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research report on Monday, August 1st.
Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. boosted its position in Adma Biologics by 41.0% in the first quarter. Franklin Resources Inc. now owns 359,499 shares of the company’s stock worth $2,908,000 after buying an additional 104,500 shares during the last quarter. Iguana Healthcare Management LLC acquired a new position in shares of Adma Biologics during the second quarter valued at approximately $744,000. Sabby Management LLC acquired a new position in shares of Adma Biologics during the second quarter valued at approximately $595,000. Guggenheim Capital LLC boosted its position in shares of Adma Biologics by 36.3% in the second quarter. Guggenheim Capital LLC now owns 29,747 shares of the company’s stock valued at $177,000 after buying an additional 7,929 shares in the last quarter. Finally, UBS Oconnor LLC boosted its position in shares of Adma Biologics by 111.3% in the second quarter. UBS Oconnor LLC now owns 71,174 shares of the company’s stock valued at $423,000 after buying an additional 37,497 shares in the last quarter. 73.91% of the stock is owned by hedge funds and other institutional investors.
Adma Biologics (NASDAQ:ADMA) opened at 6.71 on Thursday. The firm’s market capitalization is $86.47 million. Adma Biologics has a 12 month low of $4.15 and a 12 month high of $9.85. The stock’s 50 day moving average price is $6.28 and its 200-day moving average price is $6.72.
Adma Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Friday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.11. Adma Biologics had a negative return on equity of 1,293.57% and a negative net margin of 231.85%. Equities analysts forecast that Adma Biologics will post ($1.76) earnings per share for the current year.
Adma Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adma Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adma Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.